BioAge Labs Inc (NASDAQ:BIOA) has seen 2.6 million shares traded in the recent trading session. The company, currently valued at $149.90M, closed the recent trade at $4.18 per share which meant it gained $0.08 on the day or 1.98% during that session. The BIOA stock price is -536.84% off its 52-week high price of $26.62 and 7.89% above the 52-week low of $3.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.9 million shares traded. The 3-month trading volume is 669.34K shares.
BioAge Labs Inc (NASDAQ:BIOA) trade information
Sporting 1.98% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BIOA stock price touched $4.18 or saw a rise of 17.39%. Year-to-date, BioAge Labs Inc shares have moved -77.16%, while the 5-day performance has seen it change -12.89%. Over the past 30 days, the shares of BioAge Labs Inc (NASDAQ:BIOA) have changed -76.92%. Short interest in the company has seen 2.37 million shares shorted with days to cover at 11.43.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Wall Street analysts have a consensus price target for the stock at $40, which means that the shares’ value could jump 89.55% from the levels at last check today. The projected low price target is $7.0 while the price target rests at a high of $45.0. In that case, then, we find that the latest price level in today’s session is -976.56% off the targeted high while a plunge would see the stock gain -67.46% from the levels at last check today.
BIOA Dividends
BioAge Labs Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
